Cingulate Stock (NASDAQ:CING)

Forecast Ownership Financials Chart

Previous Close

$5.26

52W Range

$3.20 - $11.89

50D Avg

$6.71

200D Avg

$4.89

Market Cap

$30.55M

Avg Vol (3M)

$490.73K

Beta

-0.77

Div Yield

CING Company Profile

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Dec 08, 2021

Website

CING Performance

CING Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-19.94M	$-15.64M	$-22.76M
Net Income	$-22.45M	$-15.55M	$-23.53M
EBITDA	$-19.94M	$-14.89M	$-22.95M
Basic EPS	$-4.13	$-10.20	$-311.99
Diluted EPS	$-4.13	$-10.20	$-311.99

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
NCNA	NuCana plc
LEXX	Lexaria Bioscience Corp.
SYBX	Synlogic, Inc.
BCTX	BriaCell Therapeutics Corp.
ALLR	Allarity Therapeutics, Inc.
LIXT	Lixte Biotechnology Holdings, Inc.
CLSD	Clearside Biomedical, Inc.